European Commission to order 1.25 million doses of Valneva’s whole-virus COVID-19 vaccine VLA2001 in 2022 Valneva, a specialty vaccine company,... View Article
Author Archives for Adeline Chauvigné
European Commission approves purchase agreement amendment for Valneva’s inactivated COVID-19 vaccine
19 May 2024European Commission to order 1.25 million doses of Valneva’s whole-virus COVID-19 vaccine VLA2001 in 2022 Valneva, a specialty vaccine company,... View Article
Focus on the Atlanpole Biotherapies 2022 General Assembly
ON TUESDAY 5th JULY, MORE THAN 150 PARTICIPANTS ATTENDED THE ATLANPOLE BIOTHERAPIES ANNUAL GENERAL ASSEMBLY. In addition to taking stock... View Article
Focus on the Atlanpole Biotherapies 2022 General Assembly
19 May 2024ON TUESDAY 5th JULY, MORE THAN 150 PARTICIPANTS ATTENDED THE ATLANPOLE BIOTHERAPIES ANNUAL GENERAL ASSEMBLY. In addition to taking stock... View Article
OSE Immunotherapeutics appoints Alexis Vandier as Chief Executive Officer
OSE Immunotherapeutics is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings... View Article
OSE Immunotherapeutics appoints Alexis Vandier as Chief Executive Officer
19 May 2024OSE Immunotherapeutics is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings... View Article
Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA
Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article
Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA
19 May 2024Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article
VitaDX and MEDIPATH collaborate to deploy VisioCyt®, an innovative solution for the early diagnosis of bladder cancer
VitaDX – a deeptech healthcare company pioneering the use of artificial intelligence and image processing in cytology – announces its... View Article
VitaDX and MEDIPATH collaborate to deploy VisioCyt®, an innovative solution for the early diagnosis of bladder cancer
19 May 2024VitaDX – a deeptech healthcare company pioneering the use of artificial intelligence and image processing in cytology – announces its... View Article
BioMAdvanced Diagnostics: agreement with Nantes University Hospital to use anonymized clinical data from 300 kidney transplant patients
📢 [Key Milestone] BioMAdvanced Diagnostics enters an agreement with Nantes’ University Hospital to analyze anonymized clinical data from 300 kidney... View Article
BioMAdvanced Diagnostics: agreement with Nantes University Hospital to use anonymized clinical data from 300 kidney transplant patients
19 May 2024📢 [Key Milestone] BioMAdvanced Diagnostics enters an agreement with Nantes’ University Hospital to analyze anonymized clinical data from 300 kidney... View Article
Naobios delivers Flugen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the... View Article
Naobios delivers Flugen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
19 May 2024Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the... View Article
Apellis expands R&D collaboration with Affilogic to develop targeted complement therapies for delivery into the brain
Apellis Pharmaceuticals and Affilogic announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed... View Article
Apellis expands R&D collaboration with Affilogic to develop targeted complement therapies for delivery into the brain
19 May 2024Apellis Pharmaceuticals and Affilogic announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed... View Article
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001 Valneva , a specialty vaccine company, today announced... View Article
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe
19 May 2024Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001 Valneva , a specialty vaccine company, today announced... View Article
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Valneva, a specialty vaccine company, today... View Article
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001
19 May 2024VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Valneva, a specialty vaccine company, today... View Article